The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 13.26 — safe zoneOK
- Earnings-manipulation signal · Beneish M -3.28 — no flag raisedOK
- Earnings quality 86/100 — accruals in line with cashOK
Leadership changes
From BioNexus Gene Lab Corp's own filings, the day they're filed.
- Chong Set Fui · Chief Financial Officer · appointmenteff. 2025-06-17
- Jook Yuen Low · director · appointmenteff. 2024-11-05
- Wei Li Leong · Chief Financial Officer · departureeff. 2023-10-30
Latest filings
- 8-K · Company announcement2026-06-05
- 10-Q · Quarterly report2026-05-15
- 10-K · Annual report2026-04-14
- 8-K · Company announcement2026-03-17
- 8-K · Company announcement2026-02-23
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about BioNexus Gene Lab Corp, every answer cited🔒
- The Intelligence Brief — added when BioNexus Gene Lab Corp's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.